Literature DB >> 26853143

Door to Intravenous Tissue Plasminogen Activator Time and Hospital Length of Stay in Acute Ischemic Stroke Patients, Georgia, 2007-2013.

Moges Seyoum Ido1, Ike S Okosun2, Rana Bayakly3, Lydia Clarkson3, James Lugtu3, Sanita Floyd3, Kerrie Krompf4, Michael Frankel4.   

Abstract

BACKGROUND: Ischemic stroke patients benefit most from intravenous thrombolysis when they receive the treatment as quickly as possible after symptom onset. Hospitals participating in the Georgia Coverdell Acute Stroke Registry reduced the time from patient arrival to administration of intravenous tissue plasminogen activator. This study evaluates the benefit of reducing door-to-treatment (DTT) time as measured by hospital length of stay (LOS).
METHODS: Data from 3154 ischemic stroke patients treated with intravenous thrombolysis from 2007 to 2013 were analyzed. The impact of door-to-treatment time on patients' length of hospital stay, discharge disposition, ambulatory status at discharge, and bleeding complications was assessed, controlling for patient-, hospital- and event-related characteristics.
RESULTS: Patients who received intravenous thrombolysis within 30 minutes of hospital arrival had a 19% shorter (95% confidence interval [CI]: 2%-32%, P value = .04) hospital LOS than those treated for more than 120 minutes after arrival. Patients treated within 60 minutes of arrival were 27% more likely (odds ratio = 1.28, 95% CI: 1.06-1.56, P = .01) to have a better discharge disposition than patients treated after 60 minutes of arrival while having a similar rate of bleeding complications.
CONCLUSIONS: Shortening the door-to-treatment time is associated with a decrease in patient LOS and better patient outcomes. Hospitals should be encouraged to measure, monitor, and reduce DTT time progressively for a better patient outcome.
Copyright © 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ischemic stroke; door-to-treatment time; hospital length of stay; intravenous thrombolysis; patient outcome; tissue plasminogen activator

Mesh:

Substances:

Year:  2016        PMID: 26853143     DOI: 10.1016/j.jstrokecerebrovasdis.2015.12.025

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  3 in total

1.  Disparities and Trends in Door-to-Needle Time: The FL-PR CReSD Study (Florida-Puerto Rico Collaboration to Reduce Stroke Disparities).

Authors:  Sofia A Oluwole; Kefeng Wang; Chuanhui Dong; Maria A Ciliberti-Vargas; Carolina M Gutierrez; Li Yi; Jose G Romano; Enmanuel Perez; Brittany Ann Tyson; Maranatha Ayodele; Negar Asdaghi; Hannah Gardener; David Z Rose; Enid J Garcia; Juan Carlos Zevallos; Dianne Foster; Mary Robichaux; Salina P Waddy; Ralph L Sacco; Tatjana Rundek
Journal:  Stroke       Date:  2017-07-13       Impact factor: 7.914

2.  A Retrospective Clinical Evaluation of an Artificial Intelligence Screening Method for Early Detection of STEMI in the Emergency Department.

Authors:  Dongsung Kim; Ji Eun Hwang; Youngjin Cho; Hyoung-Won Cho; Wonjae Lee; Ji Hyun Lee; Il-Young Oh; Sumin Baek; Eunkyoung Lee; Joonghee Kim
Journal:  J Korean Med Sci       Date:  2022-03-14       Impact factor: 2.153

3.  Impact of intravenous thrombolysis on length of hospital stay in cases of acute ischemic stroke.

Authors:  Narongrit Kasemsap; Nisa Vorasoot; Kannikar Kongbunkiat; Udomlack Peansukwech; Somsak Tiamkao; Kittisak Sawanyawisuth
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-09       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.